SEATTLE--(BUSINESS WIRE)--Kayothera, Inc. (“Kayothera”), a preclinical therapeutics company developing first-in-class, small molecule inhibitors of the retinoid nuclear receptor pathway, today ...
A study led by researchers at the Hospital del Mar Research Institute advances one of the most significant milestones in breast cancer treatment, making immunotherapy effective against the most common ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results